| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.EJPHAR.2007.01.053 |
| P698 | PubMed publication ID | 17336290 |
| P2093 | author name string | Ben A Bahr | |
| David A Karanian | |||
| David Butler | |||
| Jennifer Bendiske | |||
| Mary L Michaelis | |||
| P433 | issue | 1-2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 20-27 | |
| P577 | publication date | 2007-02-08 | |
| P1433 | published in | European Journal of Pharmacology | Q1376712 |
| P1476 | title | Microtubule-stabilizing agent prevents protein accumulation-induced loss of synaptic markers | |
| P478 | volume | 562 |
| Q33310236 | Amyloid-beta peptide binds to microtubule-associated protein 1B (MAP1B). |
| Q37576090 | An update on treatment and prevention strategies for Alzheimer's disease |
| Q48466579 | Blast waves from detonated military explosive reduce GluR1 and synaptophysin levels in hippocampal slice cultures |
| Q37947984 | Convergent pathogenic pathways in Alzheimer's and Huntington's diseases: shared targets for drug development. |
| Q39038619 | Correlation analysis of the taxane core functional group modification, enzyme expression, and metabolite accumulation profiles under methyl jasmonate treatment |
| Q37827489 | Current perspectives on pharmacotherapy of Alzheimer's disease |
| Q34067487 | Current treatment and recent clinical research in Alzheimer's disease |
| Q33916749 | Drug candidates in clinical trials for Alzheimer's disease |
| Q41941624 | Gephyrin alterations due to protein accumulation stress are reduced by the lysosomal modulator Z-Phe-Ala-diazomethylketone |
| Q27304753 | Identification of microtubule growth deceleration and its regulation by conserved and novel proteins. |
| Q47959346 | Inhibitor of Endocannabinoid Deactivation Protects Against In Vitro and In Vivo Neurotoxic Effects of Paraoxon |
| Q26865358 | Mitochondrial abnormalities in Alzheimer's disease: possible targets for therapeutic intervention |
| Q38162441 | Notch signalling in adult neurons: a potential target for microtubule stabilization. |
| Q55053333 | Paraoxon: An Anticholinesterase That Triggers an Excitotoxic Cascade of Oxidative Stress, Adhesion Responses, and Synaptic Compromise. |
| Q37198579 | Pharmacological Treatment of Alzheimer's Disease: Is it Progressing Adequately? |
| Q28771363 | Phosphatase 2A Inhibition Affects Endoplasmic Reticulum and Mitochondria Homeostasis Via Cytoskeletal Alterations in Brain Endothelial Cells |
| Q35904520 | Positive lysosomal modulation as a unique strategy to treat age-related protein accumulation diseases |
| Q34847609 | Preventing Alzheimer's disease : separating fact from fiction |
| Q30535298 | Reducing HDAC6 ameliorates cognitive deficits in a mouse model for Alzheimer's disease |
| Q53393272 | Selective loss of P2Y2 nucleotide receptor immunoreactivity is associated with Alzheimer's disease neuropathology. |
| Q38036916 | Targeting synaptic dysfunction in Alzheimer's disease therapy. |
| Q41945501 | Tau pathology: predictive diagnostics, targeted preventive and personalized medicine and application of advanced research in medical practice |
| Q26739412 | Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's Disease |
| Q50632272 | Tau-based therapeutics for Alzheimer's disease: active and passive immunotherapy. |
| Q38715233 | Tau-directed approaches for the treatment of Alzheimer's disease: focus on leuco-methylthioninium |
| Q37357119 | Taxol biosynthesis: Identification and characterization of two acetyl CoA:taxoid-O-acetyl transferases that divert pathway flux away from Taxol production |
| Q35216140 | The toxicity of tau in Alzheimer disease: turnover, targets and potential therapeutics |
| Q81527536 | Therapeutic strategies for Alzheimer's disease |
Search more.